Literature DB >> 25042457

What is pharmacological 'affinity'? Relevance to biased agonism and antagonism.

Terry Kenakin1.   

Abstract

The differences between affinity measurements made in binding studies and those relevant to receptor function are described. There are theoretical and practical reasons for not utilizing binding data and, in terms of the quantification of signaling bias, it is unnecessary to do so. Finally, the allosteric control of ligand affinity through receptor-signaling protein interaction is discussed within the context of biased antagonism. In this regard, it is shown that both the bias and relative efficacy of a ligand are essential data for fully predicting biased effects in vivo.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Keywords:  biased agonism; biased signaling; receptor theory

Mesh:

Substances:

Year:  2014        PMID: 25042457     DOI: 10.1016/j.tips.2014.06.003

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  27 in total

1.  Quantitative structural assessment of graded receptor agonism.

Authors:  Jinsai Shang; Richard Brust; Patrick R Griffin; Theodore M Kamenecka; Douglas J Kojetin
Journal:  Proc Natl Acad Sci U S A       Date:  2019-10-14       Impact factor: 11.205

Review 2.  Gaddum Memorial Lecture 2014: receptors as an evolving concept: from switches to biased microprocessors.

Authors:  Terry Kenakin
Journal:  Br J Pharmacol       Date:  2015-07-21       Impact factor: 8.739

3.  Bias analyses of preclinical and clinical D2 dopamine ligands: studies with immediate and complex signaling pathways.

Authors:  Tarsis F Brust; Michael P Hayes; David L Roman; Kevin D Burris; Val J Watts
Journal:  J Pharmacol Exp Ther       Date:  2014-12-24       Impact factor: 4.030

4.  Modulation of opioid receptor affinity and efficacy via N-substitution of 9β-hydroxy-5-(3-hydroxyphenyl)morphan: Synthesis and computer simulation study.

Authors:  Phong M Truong; Sergio A Hassan; Yong-Sok Lee; Theresa A Kopajtic; Jonathan L Katz; Aaron M Chadderdon; John R Traynor; Jeffrey R Deschamps; Arthur E Jacobson; Kenner C Rice
Journal:  Bioorg Med Chem       Date:  2017-03-01       Impact factor: 3.641

Review 5.  Monoamine reuptake inhibitors in Parkinson's disease.

Authors:  Philippe Huot; Susan H Fox; Jonathan M Brotchie
Journal:  Parkinsons Dis       Date:  2015-02-25

6.  Interaction of fenoterol stereoisomers with β2-adrenoceptor-G sα fusion proteins: antagonist and agonist competition binding.

Authors:  Michael T Reinartz; Solveig Kälble; Irving W Wainer; Roland Seifert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-01-31       Impact factor: 3.000

7.  The great divide: Separation between in vitro and in vivo effects of PSNCBAM-based CB1 receptor allosteric modulators.

Authors:  Thomas F Gamage; Charlotte E Farquhar; Timothy W Lefever; Brian F Thomas; Thuy Nguyen; Yanan Zhang; Jenny L Wiley
Journal:  Neuropharmacology       Date:  2017-08-10       Impact factor: 5.250

8.  Molecular mechanisms of serotonergic action of the HIV-1 antiretroviral efavirenz.

Authors:  Dhwanil A Dalwadi; Seongcheol Kim; Shahnawaz M Amdani; Zhenglan Chen; Ren-Qi Huang; John A Schetz
Journal:  Pharmacol Res       Date:  2016-05-06       Impact factor: 7.658

9.  Distinct Signaling Patterns of Allosteric Antagonism at the P2Y1 Receptor.

Authors:  Zhan-Guo Gao; Kenneth A Jacobson
Journal:  Mol Pharmacol       Date:  2017-09-01       Impact factor: 4.436

Review 10.  Endogenously produced nonclassical vitamin D hydroxy-metabolites act as "biased" agonists on VDR and inverse agonists on RORα and RORγ.

Authors:  Andrzej T Slominski; Tae-Kang Kim; Judith V Hobrath; Allen S W Oak; Edith K Y Tang; Elaine W Tieu; Wei Li; Robert C Tuckey; Anton M Jetten
Journal:  J Steroid Biochem Mol Biol       Date:  2016-09-28       Impact factor: 4.292

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.